The Authors' Reply
Year of publication: |
2010
|
---|---|
Authors: | McCullagh, Laura ; Tilson, Lesley ; Walsh, Cathal ; Barry, Michael |
Published in: |
PharmacoEconomics. - Springer Healthcare | Adis, ISSN 1170-7690. - Vol. 28.2010, 9, p. 784-785
|
Publisher: |
Springer Healthcare | Adis |
Subject: | Anticoagulants | therapeutic use | Antithrombotics | Ardeparin-sodium | Cost-effectiveness | Dabigatran-etexilate | Dalteparin-sodium | Deep-vein-thrombosis | prevention | Enoxaparin-sodium | Factor-Xa-inhibitors | Fondaparinux-sodium | Low-molecular-weight-heparins | Pulmonary-embolism | Research-and-development | Rivaroxaban | Tinzaparin-sodium | Warfarin |
Saved in:
Online Resource
Extent: | application/pdf text/html |
---|---|
Type of publication: | Article |
Classification: | C - Mathematical and Quantitative Methods ; D - Microeconomics ; I - Health, Education, and Welfare ; Z - Other Special Topics ; I1 - Health ; I19 - Health. Other ; I18 - Government Policy; Regulation; Public Health ; I11 - Analysis of Health Care Markets |
Source: |
Persistent link: https://www.econbiz.de/10010614318